About Altoida
We envision a future where precision brain diagnosis at scale transforms neurological care, accelerates clinical trials, expands access to breakthrough treatments, and supports earlier, more informed decision-making for patients and their loved ones.
Altoida is defining a new category in neurological care with a first-of-its-kind, multi-modal platform engineered to bring clinical-grade cognitive and functional diagnostics to the front lines of healthcare. Combining augmented reality (AR), sensor fusion and explainable AI, Altoida's Digital NeuroMarker Platform delivers a 10-minute, self-administered assessment designed for both in-clinic and remote use, capturing hundreds of digital biomarkers across motor, speech, AR and cognitive domains. The platform is intended to detect signs of Mild Cognitive Impairment (MCI) and Alzheimer's disease earlier and more objectively than traditional clinical methods.
Altoida doesn't just aim to detect earlier – it's designed to get smarter. The platform is engineered to evolve continuously as it ingests multimodal, real-world data – fueling a learning loop that sharpens precision, expands across disease states and compounds both clinical and commercial value. Backed by over 20 years of scientific research, shaped by nearly 20,000 participants and tens of thousands of assessments, Altoida's platform is already being used in research by global pharmaceutical leaders to support clinical trial enrichment, optimized screening, treatment monitoring and disease progression research. Our work has been featured in Nature Digital Medicine and other leading journals.
By delivering scalable, real-time diagnostics that fit seamlessly into primary care workflows, Altoida aims to expand access to critical cognitive evaluations – empowering providers to identify at-risk individuals earlier and intervene when it matters most.
With platform extensibility ranging from Parkinson's and traumatic brain injury to depression and beyond, Altoida is building the diagnostic infrastructure for precision brain health at global scale.
Altoida's Digital NeuroMarker Platform has not received FDA clearance and is currently intended for investigational use only.
Altoida is defining a new category in neurological care with a first-of-its-kind, multi-modal platform engineered to bring clinical-grade cognitive and functional diagnostics to the front lines of healthcare. Combining augmented reality (AR), sensor fusion and explainable AI, Altoida's Digital NeuroMarker Platform delivers a 10-minute, self-administered assessment designed for both in-clinic and remote use, capturing hundreds of digital biomarkers across motor, speech, AR and cognitive domains. The platform is intended to detect signs of Mild Cognitive Impairment (MCI) and Alzheimer's disease earlier and more objectively than traditional clinical methods.
Altoida doesn't just aim to detect earlier – it's designed to get smarter. The platform is engineered to evolve continuously as it ingests multimodal, real-world data – fueling a learning loop that sharpens precision, expands across disease states and compounds both clinical and commercial value. Backed by over 20 years of scientific research, shaped by nearly 20,000 participants and tens of thousands of assessments, Altoida's platform is already being used in research by global pharmaceutical leaders to support clinical trial enrichment, optimized screening, treatment monitoring and disease progression research. Our work has been featured in Nature Digital Medicine and other leading journals.
By delivering scalable, real-time diagnostics that fit seamlessly into primary care workflows, Altoida aims to expand access to critical cognitive evaluations – empowering providers to identify at-risk individuals earlier and intervene when it matters most.
With platform extensibility ranging from Parkinson's and traumatic brain injury to depression and beyond, Altoida is building the diagnostic infrastructure for precision brain health at global scale.
Altoida's Digital NeuroMarker Platform has not received FDA clearance and is currently intended for investigational use only.